Trial Profile
A Multi-center, Open, Prospective, Phase II Study of Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Patients With Relapse and Refractory B-cell Chronic Lymphocytic Leukemia
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Shanghai Zhangjiang Biotechnology
- 15 Jun 2022 Planned End Date changed from 1 Jun 2018 to 1 Jun 2022.
- 15 Jun 2022 Status changed from recruiting to suspended.
- 21 Nov 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2018.